Claybrook Capital’s Castle Biosciences CSTL Stock Holding History

Claybrook Capital’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$169K	Sell	10,026 -3,500	-26%	-$61.2K	0.1%	133
2023 Q2	$186K	Hold	13,526	–	–	0.1%	135
2023 Q1	$307K	Buy	13,526 +3,500	+35%	+$85.5K	0.17%	108
2022 Q4	$236K	Hold	10,026	–	–	0.15%	114
2022 Q3	$261K	Hold	10,026	–	–	0.17%	107
2022 Q2	$220K	Hold	10,026	–	–	0.13%	121
2022 Q1	$450K	Hold	10,026	–	–	0.22%	97
2021 Q4	$430K	Hold	10,026	–	–	0.2%	102
2021 Q3	$667K	Buy	+10,026	New	+$706K	0.34%	76
2021 Q2	–	Sell	-10,026	Closed	-$686K	–	178
2021 Q1	$686K	Hold	10,026	–	–	0.4%	64
2020 Q4	$673K	Hold	10,026	–	–	0.44%	55
2020 Q3	$516K	Hold	10,026	–	–	0.39%	53
2020 Q2	$378K	Hold	10,026	–	–	0.32%	61
2020 Q1	$299K	Buy	+10,026	New	+$303K	0.27%	61

Other funds holding CSTL

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

KCM

Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Claybrook Capital's CSTL Position: Q3 2023 in Review

Claybrook Capital reduced its Castle Biosciences (CSTL) stake by 26% in Q3 2023, selling an estimated $61.2K and leaving 10,026 shares worth $169K. The position accounts for 0.1% of the portfolio, ranked #133.

Claybrook Capital first reported a position in CSTL in Q1 2020 and has held it in 14 quarters since. The position peaked at $686K in Q1 2021. 135 funds tracked by Wall St. Rank hold CSTL as of Q3 2023.

Claybrook Capital held 10,026 shares of Castle Biosciences worth $169K as of Q3 2023.
Claybrook Capital sold 3,500 Castle Biosciences shares in Q3 2023, an estimated $61.2K.
Castle Biosciences made up 0.1% of Claybrook Capital's portfolio in Q3 2023, its #133 holding.
Claybrook Capital first reported a position in Castle Biosciences in Q1 2020 and has held it in 14 quarters since.
Claybrook Capital's Castle Biosciences position peaked at $686K in Q1 2021.
135 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2023.

Based on Claybrook Capital's 13F filing for Q3 2023, filed 24 Oct 2023.